Policy makers may consider strategies (eg, encouraging use of biosimilar insulin) to control future insulin costs.5 Attention should also be paid to expensive medications other than insulin, because patients with diabetes are increasingly being treated with these drugs. This evidence concerns the gene INS and diabetes mellitus.